Back to results
US 2022/0017634 A1Published application
Engineered bispecific proteins
AssigneeDenali Therapeutics Inc.
InventorsGunasekaran Kannan, Do Jin Kim, Pascal Sanchez, Adam P. Silverman, Hai L. Tran
Life of this patent
Estimating the term…
Abstract
In one aspect, bispecific proteins having the ability to specifically bind to two antigens, and having an Fc polypeptide that comprises a modified CH3 domain and specifically binds to a transferrin receptor, are provided.
Claims48
A protein comprising:
- (a) a first Fc polypeptide that is fused at the N-terminus to an Fd portion of a Fab that specifically binds to a first antigen;
- (b) a second Fc polypeptide that is fused at the N-terminus to a single-chain variable fragment (scFv) that specifically binds to a second antigen, wherein the first and second Fc polypeptides form an Fc dimer;
- and
- (c) a light chain polypeptide that pairs with the Fd portion to form the Fab that specifically binds to the first antigen;
- wherein the first Fc polypeptide and/or the second Fc polypeptide comprises a modified CH3 domain and specifically binds to a transferrin receptor.
2 more elements
14-40. (canceled)
(canceled)
46-53. (canceled)
The protein of claim 53, wherein the first Fc polypeptide and/or the second Fc polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 positions selected from the following:
- position 380 is Trp, Leu, or Glu;
- position 384 is Tyr or Phe;
- position 386 is Thr;
- position 387 is Glu;
- position 388 is Trp;
- position 389 is Ser, Ala, Val, or Asn;
- position 390 is Ser or Asn;
- position 413 is Thr or Ser;
- position 415 is Glu or Ser;
- position 416 is Glu;
- and position 421 is Phe.
8 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
73-76. (canceled)
83-93. (canceled)
Dependencies are inferred from the claim text.